AVENUE THERAPEUTICS, INC. Contracts & Agreements
71 Contracts & Agreements
- Business Finance (43 contracts)
- Business Operations (5)
- Human Resources (4)
- Intellectual Property (1)
- Mergers & Acquisitions (1)
- Uncategorized (17)
- Form of Restricted Stock Unit Agreement (Filed With SEC on September 27, 2024)
- Amendment to the Avenue Therapeutics, Inc. 2015 Incentive Plan (Filed With SEC on June 26, 2024)
- At the Market Offering Agreement, dated May 10, 2024, by and between Avenue Therapeutics, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on May 13, 2024)
- Form of Investor Inducement Letter (Filed With SEC on May 1, 2024)
- Form of New Series C Warrant (May 2024) (Filed With SEC on May 1, 2024)
- Form of New Series D Warrant (May 2024) (Filed With SEC on May 1, 2024)
- Form of Placement Agent Warrant (May 2024) (Filed With SEC on May 1, 2024)
- Description of Securities of Avenue Therapeutics, Inc (Filed With SEC on March 18, 2024)
- Consulting Agreement with Dr. Jay Kranzler, dated December 1, 2020 (Filed With SEC on March 18, 2024)
- Form of New Series A Warrant (January 2024) (Filed With SEC on January 8, 2024)
- Form of New Series B Warrant (January 2024) (Filed With SEC on January 8, 2024)
- Form of January 2023 Investor Inducement Letter (Filed With SEC on January 8, 2024)
- Form of November 2023 Investor Inducement Letter (Filed With SEC on January 8, 2024)
- Form of Series B Warrant (November 2023) (Filed With SEC on November 2, 2023)
- Form of Pre-funded Warrant (November 2023) (Filed With SEC on November 2, 2023)
- Warrant Agent Agreement, dated October 31, 2023 by and between Avenue Therapeutics, Inc. and VStock Transfer, LLC (Filed With SEC on November 2, 2023)
- Placement Agency Agreement dated October 31, 2023, by and among Avenue Therapeutics, Inc., Maxim Group LLC and Lake Street Capital Markets, LLC (Filed With SEC on November 2, 2023)
- Form of Securities Purchase Agreement, dated October 31, 2023, by and among Avenue Therapeutics, Inc. and the investors party thereto (Filed With SEC on November 2, 2023)
- Form of Series A Warrant (November 2023) (Filed With SEC on November 2, 2023)
- Form of Placement Agency Agreement (Filed With SEC on October 24, 2023)
- Form of Warrant (Filed With SEC on October 24, 2023)
- Form of Warrant Agent Agreement (Filed With SEC on October 24, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on October 24, 2023)
- Form of Pre-funded Warrant (Filed With SEC on September 29, 2023)
- Form of Warrant Agent Agreement (Filed With SEC on September 29, 2023)
- Registration Rights Letter Agreement, dated September 8, 2023, by and among the Company and the purchaser parties thereto (Filed With SEC on September 8, 2023)
- Form of Avenue Therapeutics, Inc. Stock Option Agreement (Filed With SEC on July 5, 2023)
- Registration Rights Agreement by and between the Company and AnnJi Pharmaceutical Co. Ltd., dated February 28, 2023 (Filed With SEC on May 12, 2023)
- AnnJi License Agreement by and between the Company and AnnJi Pharmaceutical Co. Ltd., dated February 28, 2023 (Filed With SEC on May 12, 2023)
- Description of Securities of Avenue Therapeutics, Inc (Filed With SEC on March 31, 2023)
- Amendment to the Avenue Therapeutics, Inc. 2015 Incentive Plan (Filed With SEC on February 3, 2023)
- Form of Securities Purchase Agreement (PIPE), dated January 27, 2023, by and among the Company and the purchaser party thereto (Filed With SEC on February 1, 2023)
- Form of Securities Purchase Agreement (Registered Offering), dated January 27, 2023, by and among the Company and the purchaser party thereto (Filed With SEC on February 1, 2023)
- Form of Pre-Funded Warrant (Registered Offering) (Filed With SEC on February 1, 2023)
- Form of PIPE Warrant (PIPE) (Filed With SEC on February 1, 2023)
- Form of Registration Rights Agreement, dated January 27, 2023, by and among the Company and the purchaser party thereto (Filed With SEC on February 1, 2023)
- Form of Lockup Agreement (Filed With SEC on February 1, 2023)
- Placement Agent Agreement entered into by and between the Company and Aegis Capital Corp., dated January 27, 2023 (Filed With SEC on February 1, 2023)
- Warrant Agent Agreement, dated October 6, 2022, by and between the Company and VStock Transfer, LLC (Filed With SEC on October 12, 2022)
- Form of Pre-funded Warrant (Filed With SEC on October 12, 2022)
- Form of Warrant (Filed With SEC on October 12, 2022)
- Underwriting Agreement, dated October 6, 2022, by and between the Company and Aegis Capital Corp (Filed With SEC on October 12, 2022)
- Form of Warrant Agent Agreement (Filed With SEC on October 5, 2022)
- Form of Pre-funded Warrant (Filed With SEC on October 5, 2022)
- Form of Warrant (Filed With SEC on October 5, 2022)
- Form of Underwriting Agreement (Filed With SEC on October 5, 2022)
- Stock Contribution Agreement between Avenue Therapeutics, Inc. and Fortress Biotech, Inc., dated May 11, 2022 (Filed With SEC on August 15, 2022)
- Description of Securities of Avenue Therapeutics, Inc (Filed With SEC on March 25, 2022)
- Underwriting Agreement, dated December 12, 2021, between Avenue Therapeutics, Inc. and Aegis Capital Corp., as representative of the several underwriters named therein (Filed With SEC on December 13, 2021)
- Underwriting Agreement, dated November 9, 2021, between Avenue Therapeutics, Inc. and AEGIS Capital Corp., as representative of the several underwriters named therein (Filed With SEC on November 10, 2021)
- Description of Securities (Filed With SEC on March 31, 2021)
- Facility Agreement, dated June 12, 2020, by and between Avenue Therapeutics, Inc., InvaGen Pharmaceuticals Inc., and Fortress Biotech, Inc (Filed With SEC on August 14, 2020)
- Description of Securities (Filed With SEC on March 30, 2020)
- Form of CVR Agreement (Filed With SEC on February 11, 2019)
- Registration Rights Agreement, dated February 8, 2019, by and between Avenue Therapeutics, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on February 11, 2019)
- Indemnification Agreement, dated as of November 12, 2018, by and between Fortress Biotech, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 14, 2018)
- Stock Purchase and Merger Agreement, dated as of November 12, 2018, by and between Avenue Therapeutics, Inc., InvaGen Pharmaceuticals Inc. and Madison Pharmaceuticals Inc (Filed With SEC on November 14, 2018)
- Stockholders Agreement, dated as of November 12, 2018, by and between Avenue Therapeutics, Inc., Fortress Biotech, Inc., Dr. Lucy Lu, M.D. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 14, 2018)
- Credit Agreement, dated as of November 12, 2018, by and between Avenue Therapeutics, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 14, 2018)
- Guaranty, dated as of November 12, 2018, by and between Fortress Biotech, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 14, 2018)
- Voting and Support Agreement, dated as of November 12, 2018, by and between Avenue Therapeutics, Inc., Fortress Biotech, Inc., Dr. Lucy Lu, M.D. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 14, 2018)
- Waiver Agreement, dated as of November 12, 2018, by and between Avenue Therapeutics, Inc., Fortress Biotech, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 14, 2018)
- Restrictive Covenant Agreement, dated as of November 12, 2018, by and between Fortress Biotech, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 14, 2018)
- Restrictive Covenant Agreement, dated as of November 12, 2018, by and between Dr. Lucy Lu, M.D. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 14, 2018)
- First Amendment to Executive Employment Agreement, dated as of November 12, 2018, by and between Avenue Therapeutics, Inc. and Dr. Lucy Lu, M.D (Filed With SEC on November 14, 2018)
- Amendment No. 1 to Promissory Note from Avenue Therapeutics, Inc. to Fortress Biotech, Inc. effective as of May 15, 2017 (Filed With SEC on March 1, 2018)
- Amendment No. 1 to Management Services Agreement between Fortress Biotech, Inc. and Avenue Therapeutics, Inc., effective as of May 15, 2017 (Filed With SEC on March 1, 2018)
- Avenue Therapeutics, Inc. 2 Gansevoort Street, Th Floor, New York, NY 10014 www.avenuetx.com (Filed With SEC on August 15, 2017)
- [__________] Shares* Avenue Therapeutics, Inc. Common Stock FORM OF UNDERWRITING AGREEMENT (Filed With SEC on June 23, 2017)
- [__________] Shares* Avenue Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on May 22, 2017)
- Amendment 2 to Asset Transfer andLicense Agreement (Filed With SEC on May 22, 2017)
